Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.47 |
| ▸ | CHUK | O15111 | 9/20 | 0.47 |
| ▸ | ERN1 | O75460 | 1/20 | 0.47 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | KIT | P10721 | 1/20 | 0.47 |
| ▸ | CDK11B | P21127 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.47 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.47 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.47 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.47 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.47 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.47 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815341 | 0.91 | IKBKB (0.56) | IKBKBCHUKERN1RPS6KA4PRKD3 | |
| SCHEMBL2816936 | 0.89 | IKBKB (0.51) | IKBKBCHUKERN1RPS6KA4PRKD3 | |
| SCHEMBL2813932 | 0.86 | MAPT (0.51) | IKBKBCHUKMAPTADORA2AADORA3 | |
| SCHEMBL122794 | 0.86 | MAPT (0.47) | MAPTADORA2AADORA3KDM4EKMT2A | |
| SCHEMBL2818040 | 0.85 | IKBKB (0.48) | IKBKBCHUKERN1RPS6KA4PRKD3 | |
| SCHEMBL2819760 | 0.85 | IKBKB (0.48) | IKBKBCHUKERN1RPS6KA4PRKD3 | |
| SCHEMBL2817629 | 0.85 | IKBKB (0.48) | IKBKBCHUKERN1RPS6KA4PRKD3 | |
| SCHEMBL2820826 | 0.85 | IKBKB (0.48) | IKBKBCHUKERN1RPS6KA4PRKD3 | |
| SCHEMBL2818783 | 0.84 | IKBKB (0.46) | IKBKBCHUKERN1RPS6KA4PRKD3 | |
| SCHEMBL2820522 | 0.82 | IKBKB (0.46) | IKBKBCHUKERN1RPS6KA4PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | claimed |
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | claimed |
| EP-2205602-B1 | IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS | UNIV MONTPELLIER (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-8378098-B2 | Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers | UNIVERSITE DE MONTPELLIER I (FR) | 2013-02-19 | — | — | US | disclosed |
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | UNIVERSITE DE MONTPELLIER I | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249142-A1 | IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS | IDH3A, NRAS, KRAS | IKBKB 855/4885CHUK 409/4885ERN1 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.